Skip to main content
Journal cover image

Treatment of SLE Patients with the Immunoproteasome Inhibitor KZR-616: Results from the First 3 Cohorts of an Open-Label Phase 1b Dose Escalation Trial

Publication ,  Conference
Furie, R; Bomba, D; Dall'Era, M; Khan, A; Soneira, M; Anderl, J; Wang, J; Kirk, C; Goel, N
Published in: ARTHRITIS & RHEUMATOLOGY
October 1, 2019

Duke Scholars

Published In

ARTHRITIS & RHEUMATOLOGY

EISSN

2326-5205

ISSN

2326-5191

Publication Date

October 1, 2019

Volume

71

Publisher

WILEY

Related Subject Headings

  • 3204 Immunology
  • 3202 Clinical sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Furie, R., Bomba, D., Dall’Era, M., Khan, A., Soneira, M., Anderl, J., … Goel, N. (2019). Treatment of SLE Patients with the Immunoproteasome Inhibitor KZR-616: Results from the First 3 Cohorts of an Open-Label Phase 1b Dose Escalation Trial. In ARTHRITIS & RHEUMATOLOGY (Vol. 71). WILEY.
Furie, Richard, Darrin Bomba, Maria Dall’Era, Amber Khan, Miguel Soneira, Janet Anderl, Jinhai Wang, Christopher Kirk, and Niti Goel. “Treatment of SLE Patients with the Immunoproteasome Inhibitor KZR-616: Results from the First 3 Cohorts of an Open-Label Phase 1b Dose Escalation Trial.” In ARTHRITIS & RHEUMATOLOGY, Vol. 71. WILEY, 2019.
Furie R, Bomba D, Dall’Era M, Khan A, Soneira M, Anderl J, et al. Treatment of SLE Patients with the Immunoproteasome Inhibitor KZR-616: Results from the First 3 Cohorts of an Open-Label Phase 1b Dose Escalation Trial. In: ARTHRITIS & RHEUMATOLOGY. WILEY; 2019.
Furie R, Bomba D, Dall’Era M, Khan A, Soneira M, Anderl J, Wang J, Kirk C, Goel N. Treatment of SLE Patients with the Immunoproteasome Inhibitor KZR-616: Results from the First 3 Cohorts of an Open-Label Phase 1b Dose Escalation Trial. ARTHRITIS & RHEUMATOLOGY. WILEY; 2019.
Journal cover image

Published In

ARTHRITIS & RHEUMATOLOGY

EISSN

2326-5205

ISSN

2326-5191

Publication Date

October 1, 2019

Volume

71

Publisher

WILEY

Related Subject Headings

  • 3204 Immunology
  • 3202 Clinical sciences